GeNeuro closes €17.5 million private placement
Share this article
GeNeuro secures investment to further clinical trials
GeNeuro, the Geneva-based biopharmaceutical company, announced on 31 January 2020 the securing of a €17.5 international private placement.
This investment will support the company in competing its clinical trial of temelimab in multiple sclerosis patients, as well as advance the preclinical programme for ALS and more.